Natera stock enters earnings week after new oncology data
Published on 10/31/2026 at 10:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSEarnings And Oncology In Focus
- Natera will release third-quarter results after the market closes on November 5, followed by a conference call at 4:30 p.m. ET.
- ESMO findings highlighted Signatera testing across bladder, lung, endometrial, breast and other cancers.
- Investors now face a near-term earnings catalyst alongside expanding clinical evidence for Natera's oncology portfolio.
Natera enters the new week with two company-specific catalysts in focus. On Thursday, October 29, the company said in a Natera announcement that it will release results for the quarter ended September 30 after the market closes on Thursday, November 5. Management plans to hold a conference call at 4:30 p.m. Eastern Time.
November Results Set The Tone
The earnings release will give investors the next update on revenue growth, testing volumes and profitability. The scheduled call also provides management with an opportunity to discuss demand across oncology, women's health and organ health, as well as priorities for the final quarter.
Natera stock traded at 371.25 euros on Lang & Schwarz at 10:18 CET on Saturday, October 31. The quote gives investors a live indication before the US earnings event, but it does not establish a weekly Xetra closing-price comparison.
For the scheduled release, investors can use the company's financial update and conference call to assess whether operating momentum is carrying into the second half of the year. The timing makes November 5 the next clearly defined event for the stock.
ESMO Expands Oncology Evidence
On Tuesday, October 27, Natera reported that its oncology portfolio featured in 25 ESMO abstracts, including 9 oral presentations. The company's ESMO summary highlighted phase III VOLGA findings in muscle-invasive bladder cancer and results involving Signatera ctDNA dynamics.
In the VOLGA analysis, patients who remained Signatera-negative had a 24-month event-free survival rate of 91%. The corresponding rates were 81% for patients who cleared ctDNA before surgery and 55% for those who remained positive. Natera also cited findings in lung, endometrial, breast, colorectal and gastroesophageal cancer studies.
These findings strengthen the clinical narrative around Natera's oncology portfolio, while the earnings release will show whether that narrative is translating into business performance. The two events leave the stock facing both an evidence update and a financial test in quick succession.
The broader US equity market remains the relevant backdrop for Natera stock; see the Nasdaq Composite for current market reports.
For more company coverage, see More news and analyses on Natera stock.
Natera stock at a glance
- Company: Natera, Inc.
- ISIN: US6323071042
- Ticker: NTRA
- Home exchange: Nasdaq
- Lang & Schwarz quote: 371.25 euros on Saturday, October 31, 2026, at 10:18 CET
- Next event: Third-quarter 2026 results on Thursday, November 5, 2026, after the US market close
